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Objectives: Seasonal influenza causes substantial public health burden world-
wide. Currently, trivalent vaccines containing two strains of influenza A and one of 
the two circulating influenza B strain lineages (Yamagata and Victoria) are mostly 
used. In recent years, the co-circulation of these two influenza B lineages has cre-
ated some mismatch with the recommended vaccine. The objective is to summa-
rize the epidemiology, burden and seasonality of influenza B in nine European 
countries: Switzerland, Austria, Belgium, Luxembourg, Finland, Greece, Czech 
Republic, Slovakia and Estonia. MethOds: Comprehensive review of PubMed and 
Cochrane library as of the year 2003. Additionally, a search in other data sources, 
such as websites of WHO, ECDC and national surveillance for influenza was per-
formed. Results: 10 peer-reviewed articles were included: 10 reported on epi-
demiology, 6 on disease burden and 3 on circulating strains. From grey literature, 
additional data on influenza B circulating lineages and vaccine were provided. 
Incidence data were only available for Finland. No information was found on inci-
dence or prevalence of influenza B for any other country. Articles lacked a defined 
catchment population and only proportions of influenza B among a specified popu-
lation or surveillance samples could be obtained. Though Influenza B-associated 
hospitalization rate among children < 1 year was reported in one article for Finland, 
no additional information was found on influenza B-associated hospitalizations or 
outpatient visits or emergency room for any of the other countries. Information on 
other outcome measures for disease severity was scarce as well. Seasonal variation 
and circulating strains were scarcely presented in peer-reviewed literature; some 
data were found in grey data sources though. cOnclusiOns: While surveillance 
systems have identified the co-circulation of 2 influenza B lineages and vaccine 
mismatch, there is still a low awareness about its burden probably due to the lack 
of appropriately designed studies in the assessed countries.
PIN16
PoteNtIal ePIdemICs of drugs resIstaNt BaCterIa IN Poverty 
strICkeN CouNtrIes lIke PakIstaN
Hussain T
National University of Sciences and Technology, Islamabad, Pakistan
Objectives: Antibiotics are the only promising drugs used to control bacterial 
diseases but their inappropriate use has rendered bacteria resistant. Bacteria have 
been found resistant to all classes of antibiotics including the last line antibiotics 
carbapenems. These multidrug resistant bacteria are a constant threat to human 
health. The aim of this study was to check for pathogenic contaminants in drink-
ing water samples across Pakistan check their drug resistant level too. MethOds: 
Drinking water samples were collected from different regions across Pakistan and 
microorganisms present in these samples were identified. Kirby-Bauer disc diffu-
sion tests were used to check the pattern of antibiotic resistance. Interpretation 
was done according to Clinical and Laboratory Standards Institute (CLSI) recom-
mendations. Results: Almost all of the water samples collected were contami-
nated with bacteria or protozoans. All of the contaminated samples had Escherichia 
coli, while many of them had Cryptosporidium spp and Giardia spp. Escherichia 
coli isolates were found resistant to many groups of antibiotics including carbap-
enems (17%). Antibiotics were not helpful against Cryptosporidium and Giardia 
spp. cOnclusiOns: Because of the unhygienic living style and poverty, the threat 
of these resistant bacteria is increasing, and since carbapenems are drugs of the last 
resort such a high prevalence of resistant bacteria in drinking water is an alarming 
threat and holds the potential of future outbreaks.
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Objectives: TBE is a serious central nervous system disease, which may lead to 
permanent neurological sequelae or even death. TBE is becoming a high burden in 
many parts of Europe, Asian Russia, Siberia, Asian former USSR and Far East. The 
burden is usually expressed by only the incidence or death. DALYs give a composite 
assessment of TBEʼs burden while only the incidence or deaths does not really indi-
cate the real impact on burden. The purpose of the present study is to estimate the 
burdens from the population- and individual perspectives for TBE in Slovenia, meas-
ured in DALYs and evaluate the possibilities of reducing this burden. MethOds: 
The burden of TBE in Slovenia is estimated by using the updated DALYs’ method-
ology first introduced by Murray and co-workers in the Global Burden of Disease 
(GBD) project. Adjustment to correct for under-reporting and under-ascertainment 
is applied. Calculations were based on the health outcomes of the natural course of 
TBE. Results: From the population perspective DALYs amount to 3,450 while from 
the individual perspective they amount to 3.1. The neurological sequelae have the 
largest impact on the overall DALYs measurement for TBE. cOnclusiOns: Rising 
awareness and increasing vaccination coverage for TBE is proposed for the whole 
population to reduce the burden and provide health benefits to the population as 
a whole in Slovenia.
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Objectives: Nowadays populating a decision-making model with input data has 
become a cumbersome process due to the numerous choices of data sources. To 
tackle this issue, regulatory and re-imbursement agencies encourage “evidence 
synthesis for decision making”. To this end meta-analysis methods are gaining 
renewed interest as a means of summarizing results of multiple scientific papers 
Objectives: To describe long term outcomes of one of the first cohort of HIV 
positive patients started on antiretroviral treatment (ART) in Sub-Saharan 
Africa. MethOds: We report 10-years outcomes including mortality, retention, 
CD4-count response, viral suppression (achievement of viral load (VL) < 400 copies/
ml by month-6) and failure (2 consecutive VL> 400 copies/ml or 1 VL> 5000 cop-
ies/ml-as per WHO guidelines), drug substitution from a prospective cohort of 559 
patients initiating ART between April 2004-April 2005 and followed up for 10-years 
in Kampala, Uganda. Results: Of 559 patients, 70% were female, median age (IQR) 
was 38 (33–44) years, median CD4-count (IQR) 98 (21–163) cell/µL, VL (log10) 5.4 
(5.0–5.8) copies/ml. 414 (74%) were started on stavudine+lamivudine+nevirapine, 
145 (26%) on zidovudine+lamivudine+efavirenz. After 10 years 361 (65%) patients 
were still in the study; 123 (22%) had died; 30 (5%) were lost to follow-up; 27 (5%) 
transferred; 18 (3%) withdrew consent. Mortality was high in the first year (80/123, 
65%) and substantially reduced over time. The median gain in CD4-count (IQR) was 
of 477 (199-738) cell/µL and 321 (57.4%) reached 400 cells/µL (lower limit of normal 
CD4-count in Ugandans). 82% (388/473) with available VL at month-6 achieved viral 
suppression (VL< 400 copies/ml), and of those 44 (9.1%) experienced viral failure 
after a median time (IQR) of 45 (17-69) months on ART. 73 (13.1%) switched to second 
line regimen due to ART failure. We observed 184 drug substitutions; before the 
new WHO guidelines release (2009) 52% of these (74/142) were due to toxicity as 
compared to only 17% (7/40) after 2009. cOnclusiOns: High rate of early mortality 
due to advanced disease at presentation resulted in suboptimal retention; however 
good treatment response and first line durability was achieved in patients retained 
on treatment. Rates of drug substitution were high particularly up to 2009 due to 
the use of less tolerated regimes in this period.
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Objectives: To determine the relationship between utilization of the HIV transi-
tion clinic utilization at the Infectious Diseases Institute (HTC-IDI) and general 
wellbeing of young adults living with HIV/AIDS (YALHA). MethOds: This cross 
sectional study was conducted between March and May 2012 at the HTC-IDI in 
Kampala, Uganda. The study recruited 379 YALHA who were between the ages of 
15-24 years. HTC-IDI utilization was categorized into two levels; regular (kept all 
the appointments visits) and irregular (missed one or more appointments visits) 
utilization. The general well-being of YALHA was measured using the 18-item 
general wellbeing schedule (GWS-18). The responses to each item of the GWS-
18 were aggregated and the scores were converted to a 0-100 point scale (100= 
Highest general wellbeing status). Factor analysis was used to systematically group 
the GWS-18 questionnaire. Unpaired t-test, and multivariable logistic regression 
were used to determine the association between utilization and general wellbe-
ing. Results: The mean (SD) age was 22.5±2.0 years with an age range of 15 to 24 
years and the mean (SD) CD4 cell count was 402.3±293.3 with a range of 1-2603/µl, 
231 (60.9%) were currently on ART. Of the 379 YALHA, only 32.4% regularly utilized 
the HTC. The GWS-18 tool was highly acceptable, easily administered and was 
systematically grouped into two factors (anxiety and self-control). The overall scale 
demonstrated good internal consistency with Cronbach’s alpha of 0.82. There was 
no statistically significant association between general wellbeing and utilization of 
the HIV transition clinic. cOnclusiOns: The current study found no significant 
relationship between HTC-IDI utilization and the general well being of YALHA. 
Future studies should use longitudinal designs to ensure long-term follow up of 
the YALHA using disease specific generic tools since well-being has a tendency 
of fluctuating depending on emotional and physical feelings, which may not be 
captured in a cross sectional study.
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Objectives: Chronic infection with hepatitis C virus (HCV) is a major public 
health concern in Egypt. Prevalence data exist, but methods to estimate the epi-
demiologic burden have varied and there has been no systematic approach to 
synthesize these data. The objective of this study is to synthesize published reports 
of prevalence and estimate the total number of HCV cases in Egypt. MethOds: A 
systematic search was implemented by two reviewers in the EMBASE, Medline, and 
Cochrane databases, to identify and extract data from population-based studies 
of the epidemiologic burden of HCV in Egypt. Estimates based on laboratory-
confirmed HCV infection, published between January 1, 1995 and May 13, 2014, 
were included. Published data were supplemented with data from the National 
Blood Transfusion Center (NBTC) in Egypt. 2014 population estimates were used 
to project the number of persons infected based on synthesized prevalence esti-
mates. Results: From 630 abstracts, 23 studies were identified. The population-
based Demographic and Health Survey (DHS) estimated the prevalence of active 
infection at 9.8% and overall HCV infection at 14.9%; which is likely an underesti-
mate of e the total population affected since DHS was restricted to people 15 to 55 
years of age. Estimates from blood donors from the NBTC were ~7.5%, supporting 
the low estimate from DHS. Population-based estimates from studies conducted 
in areas of high infectivity were as high as 40 to 50% HCV prevalence. Based on 
a prevalence estimate of 15% (12-18%), approximately 13 million (10-16 million) 
people are infected with HCV in Egypt. cOnclusiOns: Although estimates of the 
prevalence of HCV vary, the wealth of evidence suggests that there is an extensive 
epidemiologic burden in Egypt. With the availability of new therapies, decision-
makers and clinicians need accurate estimate of disease prevalence to assess the 
cost-benefit ratio of new HCV treatments.
